Related Experiment Video

Updated: May 21, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small

Hong-Yang Lu1, Dan Su, Xiao-Dan Pan

  • 1Zhejiang Key Laboratory of the Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022.

Oncology Letters
|June 29, 2012
PubMed

Insights

This study identifies common gene mutations and mRNA expression in advanced non-small cell lung cancer (NSCLC). These molecular markers can guide personalized treatment selection for NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Personalized therapy is crucial for advanced non-small cell lung cancer (NSCLC).
  • Identifying molecular markers is essential for guiding targeted drug selection in NSCLC treatment.

Purpose of the Study:

  • To investigate the incidence of somatic mutations and mRNA expression levels of key genes in locally advanced NSCLC.
  • To establish molecular criteria for optimizing drug selection in NSCLC patients.

Main Methods:

  • Utilized mutant-enriched and branched DNA-liquidchip technology (bDNA-LCT).
  • Analyzed somatic mutations in EGFR, KRAS, BRAF, and PIK3CA genes.
  • Assessed mRNA expression of EGFR, ERCC1, TUBB3, and TYMS in paraffin-embedded tissues from 30 Stage IIIA NSCLC patients.

Main Results:

  • EGFR mutations detected in 6 (exons 19), 4 (exons 21), and 2 (exons 20) of 30 samples; exon 19/21 mutations correlated with EGFR mRNA expression.
  • KRAS mutations found in 2 (exons 12) and 1 (exons 13) samples; PIK3CA mutations in 3 (codon 542) samples.
  • BRAF mutations were absent. ERCC1 and TUBB3 mRNA levels were higher in adenocarcinoma than squamous cell carcinoma; TYMS mRNA was lower.

Conclusions:

  • Somatic mutations and mRNA expression patterns of common genes offer a basis for selecting molecular markers.
  • These findings support individualized treatment strategies for patients with locally advanced NSCLC.
  • The study provides a molecular foundation for personalized NSCLC therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...